Companies
/Healthcare
West Pharmaceutical Services Inc
$417.80
▲ $1.38 (+0.33%) today
Markets closed · 5:12am ET
West Pharmaceutical Services (WST) Earnings History & Trends
100%
EPS beat rate
+18.65%
Avg. EPS surprise
Consecutive EPS beats
WST vs Market · 30-day return after each reportWSTS&P 500
WST EPS Trend · estimate vs actualEstimateActual
WST Revenue Trend · estimate vs actualEstimateActual
How Often Does West Pharmaceutical Services Beat Earnings Estimates?
West Pharmaceutical Services beat EPS estimates in 6 of its last 6 reported quarters, and has beaten 6 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Adjusted EPS excludes a net $54.0 million pre-tax M&A benefit (mainly a $55.7 million gain on the SmartDose 3.5mL sale to AbbVie, with a $22.4 million one-time tax cost), $6.3 million of restructuring charges, $1.8 million of other nonrecurring professional fees (legal matters, May 2026 cybersecurity incident) and amortization; GAAP diluted EPS was $3.02 | $2.66 est. $2.20 | +21.12% | $874.5M est. $826.5M | +5.80% |
| Q2 2026 | $2.37 est. $2.08 | +13.86% | $872.3M est. $840.0M | +3.85% |
| Q1 2026 | $2.13 est. $1.68 | +27.07% | $844.9M est. $779.4M | +8.41% |
| Q4 2025 | $2.04 est. $1.83 | +11.54% | $805.0M est. $794.8M | +1.28% |
| Q3 2025 | $1.96 est. $1.69 | +16.31% | $804.6M est. $787.7M | +2.15% |
| Q2 2025 | $1.84 est. $1.51 | +21.98% | $766.5M est. $726.2M | +5.55% |
Figures from SEC filings and company reports. Not investment advice.